Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to discuss outlooks on ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

Telos (NASDAQ:TLS – Get Free Report)‘s stock had its “outperform” rating reissued by Wedbush in a research note issued on Tuesday,Benzinga reports. They presently have a $6.00 target price on the ...

As previously reported, Wedbush analyst Robert Driscoll downgraded Arvinas (ARVN) to Neutral from Outperform with a price target of $12, down ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

Despite the recent rash of tech stock sell-offs, the analysts at Wedbush believe this is a short-term phenomenon, and the ...

Market fears over tariffs and growth have hit tech stocks, but Wedbush sees the dip as a buying opportunity for long-term investors ...

With Elon Musk playing a prominent role in the Trump administration, many Tesla drivers are no longer happy about supporting ...

Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research ...

Tesla stock is gaining ground on the heels of two significant news items today. President Trump made a statement of support for the company and its CEO, Elon Musk, and Wedbush put out analysis ...

Elon Musk’s role in the Trump administration is complicating his business ventures, as the tech billionaire pushes forward with efforts to slash the federal government and budget in the face of ...